LENZ TherapeuticsLENZ +5.63%12 Quick Ratio is 10.26 as of Mar. 2026, which is 27% below its 10-year median of 14.09. GuruFocus rates LENZ with a GF Score™ of 12/100. The stock has 2 warning signs investors should review. Among 1,416 Biotechnology companies, LENZ Therapeutics ranks better than 79.1% on this metric.
LENZ Therapeutics has a quick ratio of 10.26. It generally indicates good short-term financial strength.
The historical rank and industry rank for LENZ Therapeutics's Quick Ratio or its related term are showing as below:
LENZ'
s Quick Ratio Range Over the Past 10 Years
Min: 3.63 Med: 14.09 Max: 28.63
Current: 10.26
During the past 5 years, LENZ Therapeutics's highest Quick Ratio was 28.63. The lowest was 3.63. And the median was 14.09.
LENZ's Quick Ratio is ranked better than 79.1% of 1416
companies
in the Biotechnology industry
Industry Median: 3.6
vs LENZ: 10.26
LENZ Therapeutics (NAS:LENZ) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
LENZ Therapeutics Quick Ratio Related Terms
LENZ Therapeutics Quick Ratio Historical Data
* Premium members only.
The historical data trend for LENZ Therapeutics's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, LENZ Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LENZ Therapeutics Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, LENZ Therapeutics's Quick Ratio distribution charts can be found below:
* The bar in red indicates where LENZ Therapeutics's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
LENZ Therapeutics's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LENZ Therapeutics (LENZ) has a Quick Ratio of 10.26 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on LENZ Therapeutics and its competitors. This is 27% below median its historical median of 14.09. Over the past decade, LENZ Therapeutics' Quick Ratio has ranged from 3.63 to 28.63. According to the industry distribution chart, LENZ Therapeutics ranks #296 out of 1416 companies in the Biotechnology industry, placing it in the top 20.9%.
Is LENZ Therapeutics' Quick Ratio too high?
LENZ Therapeutics' current Quick Ratio of 10.26 is 27% below median its 10-year median of 14.09. Over the past 10 years, this metric has ranged from a low of 3.63 to a high of 28.63. The Biotechnology industry median Quick Ratio is 3.60. LENZ Therapeutics' value of 10.26 is 185% above this industry median. Based on the distribution chart, LENZ Therapeutics ranks #296 out of 1416 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, LENZ Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does LENZ Therapeutics' Quick Ratio compare to CNXU and CHRS?
According to the Biotechnology industry distribution chart, LENZ Therapeutics ranks #296 out of 1416 companies for Quick Ratio. This places LENZ Therapeutics in the top 21% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.60. LENZ Therapeutics' value of 10.26 is 185% above this benchmark. Historically, LENZ Therapeutics' own Quick Ratio has ranged from 3.63 to 28.63 over the past decade. While the company's 10-year median is 14.09 vs. the industry median of 3.60, LENZ Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. LENZ Therapeutics's current Quick Ratio of 10.26 is 185% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on LENZ Therapeutics and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LENZ Therapeutics's current Quick Ratio is 10.26, which is 27% below median its own 10-year median of 14.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LENZ Therapeutics stock overvalued right now?
LENZ Therapeutics (LENZ) has a current Quick Ratio of 10.26. The current Quick Ratio is 10.26, which is 27% below median its 10-year median of 14.09 and 185% above the Biotechnology industry median of 3.60. LENZ Therapeutics' overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For LENZ Therapeutics (LENZ), the current Quick Ratio is 10.26 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.
12GF Score
Get the complete analysis for LENZ
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LENZ has been successfully added to your 
